| Ytd | -58.53% | |
| 1y | -75.62% |
| Open | 1.61 | Prev Close | 1.60 | Low | 1.55 | High | 1.61 | Mkt Cap | 6.64M |
| Vol | 37.47K | Avg Vol | 124.19K | EPS | -5.16 | P/E | -0.31 | Forward P/E | -0.73 |
| Beta | 2.13 | Short Ratio | 3.31 | Inst. Own | 7.03% | Dividend | N/A | Div Yield | N/A |
| Ex Div Date | N/A | Earning | 08-18 | 50-d Avg | 1.77 | 200-d Avg | 2.90 | 1yr Est | 13.20 |
IMNN News
Imunon, Inc. (IMNN) Q2 2026 Earnings Call Transcript
Gainers AbCellera Biologics (NASDAQ:ABCL) shares increased by 8.2% to $7.5 during Friday's afte
Enrollment momentum exceeding expectations is based on highly promising survival (OS) data and well
Translational and clinical data reinforce IMNN-001's potential to unlock IL-12's anti-tumor power in
Preliminary data reinforces IMNN-001 immunotherapy's potential for success in the rapidly recruiting
Imunon Inc. (NASDAQ:IMNN) on Tuesday reported new preliminary findings from its ongoing Phase 2 mini
Imunon reports early Phase 2 data showing lower residual disease and higher ctDNA clearance with IMN
Gainers Jupiter Neurosciences (NASDAQ:JUNS) stock rose 36.4% to $0.23 during Tuesday's pre-mark
On track for enrollment of 80 participants by Q1 2027 Trial is supported by Phase 2 results showing
LAWRENCEVILLE, N. J. , June 22, 2026 (GLOBE NEWSWIRE) -- IMUNON, Inc. (NASDAQ: IMNN), a clinical-sta
Includes up-front issuance of preferred stock for $2.5 million and secured promissory notes for $7.7
Imunon, Inc. (IMNN) Q1 2026 Earnings Call Transcript
IMNN-001 is the First and Only frontline treatment candidate to demonstrate the potential for a clin
LAWRENCEVILLE, N.J., May 05, 2026 (GLOBE NEWSWIRE) -- IMUNON , Inc. (NASDAQ: IMNN), a clinical-stage
Imunon, Inc. (IMNN) Q4 2025 Earnings Call Transcript
IMNN-001 is the first frontline immunotherapy to demonstrate the potential for a clinically meaningf
The increase in median overall survival among women treated with IMNN-001 in the OVATION 2 trial ros
LAWRENCEVILLE, N.J., March 24, 2026 (GLOBE NEWSWIRE) -- IMUNON , Inc. (Nasdaq: IMNN), a clinical-sta
Imunon (NASDAQ: IMNN - Get Free Report) will likely be posting its Q4 2025 results before the market
Imunon (NASDAQ: IMNN - Get Free Report) and Pharma Mar (OTCMKTS:PHMMF - Get Free Report) are both me
Strategic Restructuring Eliminates Expenses Not Essential to the Phase 3 Study Khursheed Anwer, Ph.D
Companies Reporting Before The Bell • IDEX Biometrics (NASDAQ:IDBA) is estimated to report quarterl
Companies Reporting Before The Bell • Takeda Pharmaceutical (NYSE:TAK) is likely to report earnings
Companies Reporting Before The Bell • Creative Realities (NASDAQ:CREX) is estimated to report quart